Mosunetuzumab with polatuzumab vedotin effective in range of age groups with DLBCL
Click Here to Manage Email Alerts
NEW ORLEANS — Mosunetuzumab with polatuzumab vedotin showed efficacy in patients with diffuse large B-cell lymphoma who are younger and older than 65 years, according to research presented at the ASH Annual Meeting and Exhibition.
The overall response rate was 54% in younger patients and 72% in older patients, Adam J. Olszewski, MD, presenting author, said.
"The numbers were similar in the subgroup of patients who were previously exposed to [chimeric antigen receptor] T-cell therapy," Olszewski, associate professor of medicine at Brown University’s Warren Alpert Medical School, said.
Due to a difference in the number of lines of prior exposure among patients, researchers also evaluated response rates based on those factors.
"There was a somewhat numerically lower rate of response among younger patients who had more previous treatment exposure, but all together there was efficacy in all studied subgroups," Olszewski said.
Patients received standard dosing of polatuzumab vedotin (Polivy, Genentech), a CD79b-directed antibody-drug conjugate, every 3 weeks for six cycles, in addition to mosunetuzumab (Genentech), a CD20/CD3 T-cell engaging bispecific monoclonal antibody, for between 8 and 17 cycles.
Baseline characteristics for the subgroup analysis of the phase 1b/II study were similar in both groups, though younger patients had indicators of more advanced disease with higher lactate dehydrogenase levels and more lines of prior therapy, Olszewski said.
Primary endpoints were efficacy and safety of the combination.
Researchers noted that DLBCL commonly affects older patients who often have limited treatment options in the relapse/refractory setting due to the presence of comorbidities and other functional decline.
Collapse
Olszewski AJ, et al. Poster 1630. Presented at: ASH Annual Meeting and Exposition; Dec. 10-13, 2022; New Orleans.
Click Here to Manage Email Alerts